Find Reports

Select Report Type

Reimbursement Review

Displaying 126 - 150 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
abiraterone acetate and predni...	n/a	abiraterone acetate and prednisolone	Recommendation and Reasons Stakeholder Input Stakeholder Feedback on Draft Recommendation Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report	High-risk non-metastatic prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 23, 2022	Sep 8, 2023	PX0291-000 - PC0291-000
upadacitinib	Rinvoq	upadacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Ulcerative colitis	Reimburse with clinical criteria and/or conditions	Complete	Apr 18, 2022	Sep 1, 2023	SR0730-000
tisagenlecleucel	Kymriah	tisagenlecleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Relapsed or refractory follicular lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Feb 1, 2023	Sep 1, 2023	PG0306-000
zanubrutinib	Brukinsa	zanubrutinib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Chronic lymphocytic leukemia /small lymphocytic lymphoma.	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2023	Sep 1, 2023	PC0310-000
belzutifan	Welireg	belzutifan	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	von Hippel-Lindau disease-associated tumours	Reimburse with clinical criteria and/or conditions	Complete	Jan 23, 2023	Sep 1, 2023	PC0309-000
cenobamate	Xcopri	cenobamate	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Epilepsy, partial-onset seizures	Reimburse with clinical criteria and/or conditions	Complete	Feb 7, 2023	Aug 29, 2023	SR0770-000
dapagliflozin	N/A	dapagliflozin	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Chronic kidney disease	Reimburse with clinical criteria and/or conditions	Complete	Jun 17, 2022	Aug 23, 2023	SX0749-000 - SR0749-000
roflumilast	Zoryve	roflumilast	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Plaque psoriasis	Reimburse with clinical criteria and/or conditions	Complete	Feb 2, 2023	Aug 16, 2023	SR0771-000
cariprazine	Vraylar	cariprazine	Memorandum report to CADTH Response to the Procedural Review Panel’s Memorandum Report on the Procedural R…Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Schizophrenia	Do not reimburse	Complete	Oct 29, 2021	Aug 10, 2023	SR0708-000
avacopan	Tavneos	avacopan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Antineutrophil cytoplasmic antibody-associated vasculitis	Do not reimburse	Complete	Oct 14, 2022	Aug 10, 2023	SR0732-000
deucravacitinib	Sotyktu	deucravacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Psoriasis, moderate to severe plaque	Do not reimburse	Complete	Sep 27, 2022	Aug 8, 2023	SR0756-000
ravulizumab	Ultomiris	ravulizumab	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	AChR antibody-positive generalized Myasthenia Gravis	Do not reimburse	Complete	Oct 25, 2022	Aug 8, 2023	SR0765-000
difelikefalin	Korsuva	difelikefalin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Chronic kidney disease	Do not reimburse	Complete	Sep 22, 2022	Jul 13, 2023	SR0752-000
trastuzumab deruxtecan	Enhertu	trastuzumab deruxtecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	unresectable or metastatic HER2-low breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 13, 2022	Jun 29, 2023	PC0305-000
foslevodopa foscarbidopa	Vyalev	foslevodopa foscarbidopa	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Parkinson’s disease	Reimburse with clinical criteria and/or conditions	Complete	Nov 23, 2022	Jun 16, 2023	SR0768-000
atogepant	Qulipta	atogepant	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Migraine, prevention	Reimburse with clinical criteria and/or conditions	Complete	Feb 23, 2022	Jun 14, 2023	SR0724-000
vericiguat	Verquvo	vericiguat	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Heart failure	Reimburse with clinical criteria and/or conditions	Complete	Oct 14, 2022	Jun 14, 2023	SR0758-000
risankizumab	Skyrizi	risankizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Crohn's disease	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 12, 2023	SR0767-000
upadacitinib	Rinvoq	upadacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 17, 2022	May 11, 2023	SR0759-000
palovarotene	Sohonos	palovarotene	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Fibrodysplasia Ossificans Progressiva	Reimburse with clinical criteria and/or conditions	Complete	Oct 21, 2022	May 11, 2023	SR0761-000
selumetinib	Koselugo	selumetinib	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Neurofibromatosis type 1	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 10, 2023	SR0764-000
fostemsavir	Rukobia	fostemsavir	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Human immunodeficiency virus type 1 (HIV-1)	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 10, 2023	SR0760-000
ciltacabtagene autoleucel	Carvykti	ciltacabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Sep 23, 2022	May 1, 2023	PG0302-000
crisantaspase recombinant	Rylaze	crisantaspase recombinant	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Acute lymphoblastic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2022	Apr 26, 2023	PC0301-000
mavacamten	Camzyos	mavacamten	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Obstructive hypertrophic cardiomyopathy	Reimburse with clinical criteria and/or conditions	Complete	Sep 22, 2022	Apr 14, 2023	SR0755-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 126 - 150 of 600

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review		Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review	Jan 8, 2024	Rapid Review	Completed	RC1519-000
Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure		Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure	Jan 8, 2024	Rapid Review	Completed	RC1520-000
ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies		ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies	Dec 21, 2023	CMII Service	Completed	CM0009-000
Early Intervention Programs for Adolescents and Young Adults With Eating Disorders		Main Report Supporting Information Project Protocol	Dec 18, 2023	Health Technology Assessment	Completed	HT0040-000 - OP0552-000
Aging in Place	Our Health Technology Expert Review Panel convened to develop objective, impartial, trusted pan-Canadian guidance to inform decisions about which evidence-informed, equitable, aging in place initiatives across jurisdictions can support aging in place in Canada.	Evidence Assessment Report Supporting Information Summary of Engagement Activities Guidance	Dec 13, 2023	Optimal Use	Active	OP0555-000
Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classifications for Breast Cancer		Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classi…	Dec 7, 2023	Technology Review	Completed	HC0070-000
An Analysis of Demographic and Utilization Patterns of Patients Accessing Emergency Departments in Canada		Emergency Department Overcrowding: Utilization Analysis Emergency Department Overcrowding: Utilization Analysis: Methods Document	Nov 28, 2023	Technology Review	Complete	HC0061-000
Emergency Department Overcrowding in Canada: An Update		CADTH Guidance: Emergency Department Overcrowding Contributing Factors and Intervention Effectiveness Supporting Information: Factors and Intervention Effectiveness Multistakeholder Dialogue Protocol: Contributing Factors and Intervention Effectiveness Evidence Preview: Factors and Intervention Effectiveness	Nov 24, 2023	Optimal Use	Completed	OP0553-000 - RE0044-000
Case Carts in Surgical Settings		Case Carts in Surgical Settings	Nov 8, 2023	Rapid Review	Completed	RC1512-000
Routine Dental Polishing for Oral Health		Routine Dental Polishing for Oral Health	Nov 8, 2023	Rapid Review	Completed	RC1517-000
Intrathecal Drug Delivery Systems for Cancer Pain			Nov 6, 2023	Technology Review	Completed	HC0058-000
Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder	CADTH's Health Technology Review identifies and summarizes literature comparing the effectiveness and cost-effectiveness of sublingual buprenorphine-naloxone films versus tablets.	Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder	Nov 6, 2023	Rapid Review	Completed	RC1513-000
Intraocular Lenses for Cataract Surgery		Intraocular Lenses for Cataract Surgery	Nov 6, 2023	Rapid Review	Completed	RC1515-000
Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration		Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration	Nov 6, 2023	Rapid Review	Completed	RC1510-000
Supplemental Screening Modalities for People With Dense Breasts			Nov 1, 2023	Technology Review	Completed	HC0026-000
Refractive Laser Surgery for Vision Conditions		Refractive Laser Surgery for Vision Conditions	Oct 26, 2023	Rapid Review	Completed	RC1514-000
Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus Outcomes in Infants		Cost-Effectiveness of Nirsevimab for Prevention of Respiratory Syncytial Virus …	Oct 19, 2023	Technology Review	Completed	HE0045-000
Semaglutide 2 mg for Type 2 Diabetes		Semaglutide 2 mg for Type 2 Diabetes	Oct 19, 2023	Rapid Review	Completed	RC1507-000
Point of Care Ultrasound for Guided Central Venous Catheter Insertion		Point of Care Ultrasound for Guided Central Venous Catheter Insertion	Oct 16, 2023	Rapid Review	Completed	RC1509-000
Post–COVID-19 Condition Treatment and Management: Rapid Living Scoping Review			Oct 12, 2023	Scoping Review	Living Review	RE0040-000/RE0040-004
Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain		Radiofrequency Ablation for Chronic Knee, Hip, and Shoulder Pain	Oct 11, 2023	Rapid Review	Completed	RC1504-000
IV Acetaminophen for Acute Pain in Emergency Departments		IV Acetaminophen for Acute Pain in Emergency Departments	Oct 6, 2023	Rapid Review	Completed	RC1508-000
Perspectives and Experiences Regarding the Impacts of Emergency Department Overcrowding		Perspectives and Experiences Regarding the Impacts of Emergency Department Over…	Sep 28, 2023	Technology Review	Completed	HC0067-000
Optimizing the Use of Iodinated Contrast Media: Conservation Strategies Used Across Canada During the 2022 Shortage		CM0001-ICM-Conservation-Strategies.pdf	Sep 20, 2023	CMII Service	Completed	CM0001-000
Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection		Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection	Sep 20, 2023	Rapid Review	Completed	RC1502-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 126 - 150 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
elexacaftor/tezacaftor/ivacaftor and ivacaftor	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Mar 17, 2025	Reimbursement Review		Complete	SR0837-000
Non-small Cell Lung Cancer		Mar 13, 2025	Reimbursement Review	Provisional Funding Algorithm	Merged	PH0081-000
darolutamide		Mar 13, 2025	Reimbursement Review		Pending	PC0404-000
NSCLC without actionable oncogenic alterations		Mar 13, 2025	Reimbursement Review	Provisional Funding Algorithm	Merged	PH0059-000
guanfacine hydrochloride extended-release	Proposed Scope	Mar 13, 2025	Reimbursement Review		Pending	SX0755-000
The Cost-Effectiveness and Budget Impact of Remdesivir for Inpatient Treatment of COVID-19	The Cost-Effectiveness and Budget Impact of Remdesivir for Inpatient Treatment…Summary Report	Mar 11, 2025	Health Technology Review	Technology Review	Completed	HE0050-000
The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19	The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19 Summary Report	Mar 11, 2025	Health Technology Review	Technology Review	Completed	HE0051-000
Dosing of Immune Checkpoint Inhibitors		Mar 11, 2025	Health Technology Review	Systematic Review	In Progress	RE0053-000
The Cost-Effectiveness and Budget Impact of Nirmatrelvir-Ritonavir for COVID-19	The Cost-Effectiveness and Budget Impact of Nirmatrelvir-Ritonavir for COVID-19 Summary Report	Mar 11, 2025	Health Technology Review	Technology Review	Completed	HE0048-000
The Cost-Effectiveness and Budget Impact of Remdesivir for Outpatient Treatment of COVID-19	The Cost-Effectiveness and Budget Impact of Remdesivir for Outpatient Treatment…Summary Report	Mar 11, 2025	Health Technology Review	Technology Review	Completed	HE0049-000
pegcetacoplan	Patient and Clinician Group Input	Mar 11, 2025	Reimbursement Review		Withdrawn	SR0810-000
Environmental Scan of Genetic and Genomic Biomarker Testing Assessment Frameworks, Processes, and Inventories in Cancer Care	Final Report	Mar 7, 2025	Health Technology Review	Environmental Scan	Completed	CP0037-000
ibrutinib	Proposed Scope	Mar 6, 2025	Reimbursement Review		Received	PX0380-000
alectinib	Recommendation and Reason Patient, Clinician and Industry Group Input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Mar 5, 2025	Reimbursement Review		Complete	PC0350-000
masitinib mesylate		Mar 5, 2025	Reimbursement Review		Suspended	SR0766-000
osilodrostat		Mar 5, 2025	Reimbursement Review		Suspended	SR0804-000
risperidone		Mar 5, 2025	Reimbursement Review		Suspended	SR0811-000
Drug Shortages in Canada — Expert Panel		Mar 4, 2025	Health Technology Review	Technology Review	Completed	HC0074-000
Voice Prostheses and Heat-Moisture Exchangers for Adults following Total Laryngectomy	Draft Report - Version 2 Care for Adults Following Laryngectomy: Rapid Review Report Version 1	Mar 4, 2025	Health Technology Review	Rapid Review	Active	RC1551-000
Gastric cancer		Mar 3, 2025	Reimbursement Review		Merged	PH0080-000
trifluridine and tipiracil	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Mar 3, 2025	Reimbursement Review		Complete	PC0330-000
Multiple Myeloma		Mar 3, 2025	Reimbursement Review	Provisional Funding Algorithm	Merged	PH0060-000
Crushed Buprenorphine-Naloxone Tablets	Crushed Buprenorphine-Naloxone Tablets	Feb 28, 2025	Health Technology Review	Rapid Review	Completed	RC1570-000
Pharmaceutical Reviews Update — Issue 54		Feb 27, 2025	Reimbursement Review	Pharmaceutical Review Update
Pharmaceutical Reviews Update — Issue 55		Feb 27, 2025	Reimbursement Review	Pharmaceutical Review Update